Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1Prostate Adenocarcinoma 1

Interventions

Specimen Handling 219pembrolizumab 198Magnetic Resonance Spectroscopy 197Carboplatin 174Cisplatin 140Biopsy 133Nivolumab 131Paclitaxel 115Radiotherapy 111Cyclophosphamide 111Gemcitabine 104durvalumab 90Dexamethasone 90atezolizumab 77Radiation 72Rituximab 71Lenalidomide 69Pemetrexed 66Bevacizumab 66Doxorubicin 65Docetaxel 63Ipilimumab 59Etoposide 57olaparib 54Fluorouracil 52venetoclax 50Taxes 50Oxaliplatin 50Radiosurgery 49Prednisone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Salicylic Acid × 90 days × Clear all
NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NRG Oncology

Phase 3 Active not recruiting
2,753 enrolled
Genitourinary

Prostatic Neoplasms

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡